L. Gherasim*, S. Bălănescu*
*Prof. Dr. Leonida Gherasim, Dr. S. Bălănescu – Clinica Medicală III – Spitalul Universitar – București
Abstract
The propaphenone, an antiarrithmic from Ic – class is at present even more used in the treatment of entricular or atrial arrithmias. The main mechanism consists in the shutting off the sodium channels and second, the shutting off the calciu channels, partially beta-blokant action. Indications on the first place is malign ventricular arrithmias (in order to stop the tahiarrithmia and prophylaxy of reccurences) or in potential malign arrithmias or sometimes in ventricular arrithmias produced by effort or hypercathecolaminemy. The proarrithmic risk seems smaller than flecaini de – encainide though the propaphenone was not estimated in CAST – study. During last years there has been an experience even more rich in the treatment with propaphenone in supraventricular arrithmias: paroxistic supraventricular arrithmia, atrial fibrilation. atrial flutter or tahiarrithmias in the WPW – syndrome. The propaphenone efficiency is similar with the amiodarone’s, in these arrithmias and similar or lower than flecainide’s. The adverse reactions, some few and easly reversible, few contraindications, the high efficiency in comparison with other medicines, recommends propaphenone as an antiarrithmic of the first choice or sometimes as a very good alternative if the eligible antiarrithmic did not control the rithm troubles.